On April 21, Tom Lee, Fundstrat CIO, co-founder, and managing partner, joined ‘Squawk Box’ on CNBC to discuss the latest market trends and stated that the market may be past peak uncertainty despite the ongoing Fed uncertainties. However, Lee thinks that ‘maximum pain’ can still be anticipated, as economic risks could still cause hesitation among investors. Despite this, he believes that a structural low in fear has taken place. He acknowledged that the last low at the S&P 500 was around 4,800, which was reached a few weeks prior, and he thinks that there is a chance the market could drift dangerously close to that level in the coming weeks due to the ongoing uncertainty and investors remaining on the sidelines. Nevertheless, Lee emphasized that companies are very resilient, which should become evident during earnings season. He also mentioned the potential for a positive policy shock, such as a reduction in tariffs or de-escalation in trade tensions with countries like China, which could be seen as a win by the market, even though such developments did not seem likely overnight.

Lee also elaborated on his ‘Granny Shot’ ETF, and mentioned that the granny shots in their portfolio are stocks that, while not immune to declines, are closely linked to the most important long-term investment themes, such as cybersecurity and demographic shifts, such as the rise of millennials. The idea is to select stocks that are strongly correlated with multiple enduring themes, which increases the chances that these stocks will perform well over time, likening this to the reliability of a well-executed granny shot in basketball. Lee also noted that Bitcoin may have been held back by institutional deleveraging earlier this year, with investors selling what they could, which suppressed Bitcoin’s price, but that deleveraging process appears to be over. He now expects Bitcoin to catch up to gold and highlighted that Bitcoin’s previous high was over $110,000, which suggests that there is room for Bitcoin to appreciate as it regains momentum as a non-dollar asset. Gold recently surged to new highs, seemingly on track to reach $4,000, while Bitcoin was lagging, but it would eventually attract some of the same investment flows that were driving gold higher.

Despite potential near-term market volatility and a possible drift towards previous lows, Lee emphasizes company resilience during earnings and the potential for positive policy shocks. That being said, we’re here with a list of the 10 best cheap stocks to buy under $10.

Our Methodology

We first used the Finviz stock screener to compile a list of cheap stocks that had a forward P/E ratio under 15 and were trading under $10. We then selected the 10 stocks that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q4 2024. The hedge fund data was sourced from Insider Monkey’s database which tracks the moves of over 1000 elite money managers.

Note: All data was sourced on April 22.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

10 Best Cheap Stocks to Buy Under $10

10. Elanco Animal Health Inc. (NYSE:ELAN)

Share Price as of April 22: $8.48

Forward P/E Ratio as of April 22: 10.07

Number of Hedge Fund Holders: 37

Elanco Animal Health Inc. (NYSE:ELAN) is an animal health company that innovates, develops, and manufactures products for pets and farm animals. It offers pet health products and therapeutics under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks. It sells its products to third-party distributors and independent retailers, and directly to farm animal producers and veterinarians.

In Q4 2024, the company’s International Pet Health segment surged with an 11% increase in organic constant currency revenue. This growth primarily came from two key products: AdTab and Seresto. AdTab is a flea and tick protection product for both dogs and cats. It uses the same active ingredient as Credelio, which is growing through Elanco’s DTC strategies in Europe. This has led Elanco to revise its sales expectation for AdTab, now projecting it to exceed $100 million.

Seresto is also a flea and tick collar that provides long-lasting protection, typically around 8 months. The growth within this segment was widespread across Europe, the Middle East, Latin America, Asia Pacific, and Canada. Elanco anticipates an acceleration in its organic constant currency revenue growth to 4% to 6% for the full year 2025, driven by the strong momentum in International Pet Health.

9. Goodyear Tire & Rubber Co. (NASDAQ:GT)

Share Price as of April 22: $9.93

Forward P/E Ratio as of April 22: 7.19

Number of Hedge Fund Holders: 37

Goodyear Tire & Rubber Co. (NASDAQ:GT) develops, manufactures, distributes, and sells tires and related products and services. It offers different lines of rubber tires for applications like automobiles or earthmoving & mining equipment. It operates under different brands, such as Goodyear, Dunlop, Roadmaster, and various house brands, as well as under private-label brands.

While facing headwinds in the consumer replacement market, the US Consumer Original Equipment (OE) sector drove volume growth for Goodyear. In Q4 2024, US Consumer OE volume surged by ~20%. Despite a unit volume decrease of ~1 million units in the Americas due to challenges in the US consumer replacement market (where low-end imports saw an 11% growth), the performance of the US Consumer OE business provides a counterbalance.

Goodyear Tire & Rubber Co. (NASDAQ:GT) is now focusing on the premium tiers and blank space opportunities within the US market. It plans to introduce 5 new product lines in the US in 2025. Furthermore, Goodyear is investing in its US manufacturing capabilities. A modernization project at its Oklahoma facility is underway, which will add ~10 million units of new capacity for premium tires in 2025 and 2026.